OBJECTIVE: Patients with systemic autoimmune rheumatic diseases (ARDs) continue to be concerned about risks of severe coronavirus disease 2019 (COVID-19) outcomes. This study was undertaken to evaluate the risks of severe outcomes in COVID-19 patients with systemic ARDs compared to COVID-19 patients without systemic ARDs. METHODS: Using a large multicenter electronic health record network, we conducted a comparative cohort study of patients with systemic ARDs diagnosed as having COVID-19 (identified by diagnostic code or positive molecular test result) compared to patients with COVID-19 who did not have systemic ARDs, matched for age, sex, race/ethnicity, and body mass index (primary matched model) and additionally matched for comorbidities and health care utilization (extended matched model). Thirty-day outcomes were assessed, including hospitalization, intensive care unit (ICU) admission, mechanical ventilation, acute renal failure requiring renal replacement therapy, ischemic stroke, venous thromboembolism, and death. RESULTS: We initially identified 2,379 COVID-19 patients with systemic ARDs (mean age 58 years; 79% female) and 142,750 comparators (mean age 47 years; 54% female). In the primary matched model (2,379 patients with systemic ARDs and 2,379 matched comparators with COVID-19 without systemic ARDs), patients with systemic ARDs had a significantly higher risk of hospitalization (relative risk [RR] 1.14 [95% confidence interval (95% CI) 1.03-1.26]), ICU admission (RR 1.32 [95% CI 1.03-1.68]), acute renal failure (RR 1.81 [95% CI 1.07-3.07]), and venous thromboembolism (RR 1.74 [95% CI 1.23-2.45]) versus comparators but did not have a significantly higher risk of mechanical ventilation or death. In the extended model, all risks were largely attenuated, except for the risk of venous thromboembolism (RR 1.60 [95% CI 1.14-2.25]). CONCLUSION: Our findings indicate that COVID-19 patients with systemic ARDs may be at a higher risk of hospitalization, ICU admission, acute renal failure, and venous thromboembolism when compared to COVID-19 patients without systemic ARDs. These risks may be largely mediated by comorbidities, except for the risk of venous thromboembolism.
OBJECTIVE: Patients with systemic autoimmune rheumatic diseases (ARDs) continue to be concerned about risks of severe coronavirus disease 2019 (COVID-19) outcomes. This study was undertaken to evaluate the risks of severe outcomes in COVID-19 patients with systemic ARDs compared to COVID-19 patients without systemic ARDs. METHODS: Using a large multicenter electronic health record network, we conducted a comparative cohort study of patients with systemic ARDs diagnosed as having COVID-19 (identified by diagnostic code or positive molecular test result) compared to patients with COVID-19 who did not have systemic ARDs, matched for age, sex, race/ethnicity, and body mass index (primary matched model) and additionally matched for comorbidities and health care utilization (extended matched model). Thirty-day outcomes were assessed, including hospitalization, intensive care unit (ICU) admission, mechanical ventilation, acute renal failure requiring renal replacement therapy, ischemic stroke, venous thromboembolism, and death. RESULTS: We initially identified 2,379 COVID-19 patients with systemic ARDs (mean age 58 years; 79% female) and 142,750 comparators (mean age 47 years; 54% female). In the primary matched model (2,379 patients with systemic ARDs and 2,379 matched comparators with COVID-19 without systemic ARDs), patients with systemic ARDs had a significantly higher risk of hospitalization (relative risk [RR] 1.14 [95% confidence interval (95% CI) 1.03-1.26]), ICU admission (RR 1.32 [95% CI 1.03-1.68]), acute renal failure (RR 1.81 [95% CI 1.07-3.07]), and venous thromboembolism (RR 1.74 [95% CI 1.23-2.45]) versus comparators but did not have a significantly higher risk of mechanical ventilation or death. In the extended model, all risks were largely attenuated, except for the risk of venous thromboembolism (RR 1.60 [95% CI 1.14-2.25]). CONCLUSION: Our findings indicate that COVID-19 patients with systemic ARDs may be at a higher risk of hospitalization, ICU admission, acute renal failure, and venous thromboembolism when compared to COVID-19 patients without systemic ARDs. These risks may be largely mediated by comorbidities, except for the risk of venous thromboembolism.
Authors: Kimme L Hyrich; Milena Gianfrancesco; Pedro M Machado; Jinoos Yazdany; Philip C Robinson Journal: Ann Rheum Dis Date: 2020-09-07 Impact factor: 27.973
Authors: Erica J Brenner; Ryan C Ungaro; Richard B Gearry; Gilaad G Kaplan; Michele Kissous-Hunt; James D Lewis; Siew C Ng; Jean-Francois Rahier; Walter Reinisch; Frank M Ruemmele; Flavio Steinwurz; Fox E Underwood; Xian Zhang; Jean-Frederic Colombel; Michael D Kappelman Journal: Gastroenterology Date: 2020-05-18 Impact factor: 22.682
Authors: Rebecca Haberman; Jordan Axelrad; Alan Chen; Rochelle Castillo; Di Yan; Peter Izmirly; Andrea Neimann; Samrachana Adhikari; David Hudesman; Jose U Scher Journal: N Engl J Med Date: 2020-04-29 Impact factor: 91.245
Authors: Jose L Pablos; María Galindo; Loreto Carmona; Ana Lledó; Miriam Retuerto; Ricardo Blanco; Miguel A Gonzalez-Gay; David Martinez-Lopez; Isabel Castrejón; José M Alvaro-Gracia; David Fernández Fernández; Antonio Mera-Varela; Sara Manrique-Arija; Natalia Mena Vázquez; Antonio Fernandez-Nebro Journal: Ann Rheum Dis Date: 2020-08-12 Impact factor: 19.103
Authors: Kristin M D'Silva; Naomi Serling-Boyd; Rachel Wallwork; Tiffany Hsu; Xiaoqing Fu; Ellen M Gravallese; Hyon K Choi; Jeffrey A Sparks; Zachary S Wallace Journal: Ann Rheum Dis Date: 2020-05-26 Impact factor: 27.973
Authors: Mohamad Alkhouli; Aravinda Nanjundappa; Frank Annie; Mark C Bates; Deepak L Bhatt Journal: Mayo Clin Proc Date: 2020-05-29 Impact factor: 7.616
Authors: Angelo Porfidia; Emanuele Valeriani; Roberto Pola; Ettore Porreca; Anne W S Rutjes; Marcello Di Nisio Journal: Thromb Res Date: 2020-08-12 Impact factor: 3.944
Authors: Richard Conway; Elena Nikiphorou; Christiana A Demetriou; Candice Low; Kelly Leamy; John G Ryan; Ronan Kavanagh; Alexander D Fraser; John J Carey; Paul O'Connell; Rachael M Flood; Ronan H Mullan; David J Kane; Philip C Robinson; Jean W Liew; Rebecca Grainger; Geraldine M McCarthy Journal: Rheumatol Adv Pract Date: 2021-05-13
Authors: Zara Izadi; Milena A Gianfrancesco; Alfredo Aguirre; Anja Strangfeld; Elsa F Mateus; Kimme L Hyrich; Laure Gossec; Loreto Carmona; Saskia Lawson-Tovey; Lianne Kearsley-Fleet; Martin Schaefer; Andrea M Seet; Gabriela Schmajuk; Lindsay Jacobsohn; Patricia Katz; Stephanie Rush; Samar Al-Emadi; Jeffrey A Sparks; Tiffany Y-T Hsu; Naomi J Patel; Leanna Wise; Emily Gilbert; Alí Duarte-García; Maria O Valenzuela-Almada; Manuel F Ugarte-Gil; Sandra Lúcia Euzébio Ribeiro; Adriana de Oliveira Marinho; Lilian David de Azevedo Valadares; Daniela Di Giuseppe; Rebecca Hasseli; Jutta G Richter; Alexander Pfeil; Tim Schmeiser; Carolina A Isnardi; Alvaro A Reyes Torres; Gelsomina Alle; Verónica Saurit; Anna Zanetti; Greta Carrara; Julien Labreuche; Thomas Barnetche; Muriel Herasse; Samira Plassart; Maria José Santos; Ana Maria Rodrigues; Philip C Robinson; Pedro M Machado; Emily Sirotich; Jean W Liew; Jonathan S Hausmann; Paul Sufka; Rebecca Grainger; Suleman Bhana; Wendy Costello; Zachary S Wallace; Jinoos Yazdany Journal: ACR Open Rheumatol Date: 2022-07-22
Authors: Jeffrey R Curtis; Sindhu R Johnson; Donald D Anthony; Reuben J Arasaratnam; Lindsey R Baden; Anne R Bass; Cassandra Calabrese; Ellen M Gravallese; Rafael Harpaz; Andrew Kroger; Rebecca E Sadun; Amy S Turner; Eleanor Anderson Williams; Ted R Mikuls Journal: Arthritis Rheumatol Date: 2022-05 Impact factor: 15.483
Authors: Ruth K Topless; Amanda Phipps-Green; Megan Leask; Nicola Dalbeth; Lisa K Stamp; Philip C Robinson; Tony R Merriman Journal: ACR Open Rheumatol Date: 2021-04-15
Authors: Bryant R England; Punyasha Roul; Yangyuna Yang; Andre C Kalil; Kaleb Michaud; Geoffrey M Thiele; Brian C Sauer; Joshua F Baker; Ted R Mikuls Journal: Arthritis Rheumatol Date: 2021-10-19 Impact factor: 15.483